Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 13/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 12/20 | 0.41 |
| ▸ | ERBB3 | P21860 | 12/20 | 0.41 |
| ▸ | ERBB4 | Q15303 | 12/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.39 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4282301 | 0.80 | EGFR (0.41) | EGFRTRPA1KDRDRD1 | |
| SCHEMBL16432196 | 0.75 | TRPA1 (0.55) | DYRK1AEGFRERBB2ERBB3ERBB4 | |
| SCHEMBL4771430 | 0.74 | EGFR (0.37) | EGFRKDR | |
| SCHEMBL4771434 | 0.74 | EGFR (0.37) | EGFRKDR | |
| SCHEMBL15960748 | 0.74 | KDR (0.53) | EGFRKDRDRD1 | |
| SCHEMBL3573516 | 0.74 | AXL (0.45) | DYRK1AEGFRKDR | |
| SCHEMBL4283173 | 0.73 | KDR (0.39) | EGFRKDR | |
| SCHEMBL4284980 | 0.73 | KDR (0.56) | KDR | |
| SCHEMBL4281127 | 0.72 | EGFR (0.40) | EGFRTRPA1KDRDRD1 | |
| SCHEMBL4668514 | 0.72 | KDR (0.74) | EGFRTRPA1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TIE1, KDR, FLT1 | DYRK1A 1214/4885EGFR 20/4885ERBB2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.